This single award indefinite delivery contract from the Department of Health and Human Services' Food and Drug Administration to Laboratory Corporation of America holds a potential value of $4.6 million to provide COVID-19 testing services for FDA employees and contractors. Two firm fixed price delivery orders have been awarded against the contract to date, for $149,949.15 and $20,069.53 respectively, with periods of performance through July 2023 and March 2022. Place of performance will be Laboratory Corporation of America's facilities in Burlington, North Carolina.
No set-aside designation was applied under the contract or associated delivery orders. The original solicitation sought COVID-19 testing to support the FDA's mission during the ongoing coronavirus pandemic. As the largest commercial clinical laboratory in the United States, Laboratory Corporation of America will utilize its extensive experience and infrastructure to deliver critical coronavirus disease 2019 testing for FDA staff, aiding the agency in ensuring the safety of medical products during this public health emergency.
Generated 1/5/24, 2:00 AM